FY 2012 NIH Budget Roll-out

Francis S. Collins, M.D., Ph.D. Director, NIH





WINNING the FUTURE

"To win the future, America needs to out-educate, out-innovate, and out-build the rest of the world."

President Barack Obama, Weekly Address
 February 5, 2011

The Benefits of Biomedical and Public Health Advances: *U.S. Life Expectancy*



Life expectancy gains worth ~\$3.2 trillion annually

NIH Accomplishments

Reduction in deaths from:

- Heart disease
- Stroke
- HIV/AIDS

Increased survival rates for:


- Breast cancer
- Cervical cancer
- Colon cancer

Impact of NIH Funding



NIH FY 2012 President's Budget Request \$31,987 Million


Increase of \$ 745 M or 2.4% over FY 2010 Actuals



Note: ARRA funds were appropriated in FY 2009

FY 2012 President's Budget Request NIH Total Program Level


\$31,987 Million



NIH Advances in Basic Research 2010

132 grantees or trainees have become Nobel Laureates Most Recent: Ei-ichi Negishi of Purdue University


- Generation of "hair cells" essential for hearing
- Demonstration of the power of resolvins to control pain
- Creation of better nanotubes for drug delivery
- Identification of target for universal flu vaccine




NIH Investments in Innovation — FY 2012

- Advancing Translational Sciences
- Accelerating Discovery Through Technology
- Enhancing the Evidence Base for Health-Care Decisions
- Encouraging New Investigators and New Ideas








Therapeutics Development at NIH

- A 2010 trans-NIH inventory of activities relevant to therapeutics development found:
 - Substantial investments in therapeutics development research
 - Approximately 65% for preclinical research; 35% clinical research
 - 550 activities reported of varying sizes and areas of emphasis



Distribution of Investment

The NEW ENGLAND JOURNAL of MEDICINE

SPECIAL ARTICLE

The Role of Public-Sector Research in the Discovery of Drugs and Vaccines

Ashley J. Stevens, D.Phil., Jonathan J. Jensen, M.B.A., Katrine Wyller, M.B.E., Patrick C. Kilgore, B.S., Sabarni Chatterjee, M.B.A., Ph.D., and Mark L. Rohrbaugh, Ph.D., J.D.


N ENGL J MED 364;6 NEJM.ORG FEBRUARY 10, 2011

National Center for Advancing Translational Sciences (NCATS)


Why now? Rationale for Establishment

- Deluge of new discoveries of potential targets
- Opportunity to serve as a catalyst to further enhance longstanding therapeutic research programs in NIH Institutes and Centers
- Opportunity to conduct process engineering on therapeutic development pipeline in an open-access model, to provide innovation, and to identify predictors of success
- Unexplored opportunities for therapeutics for many conditions, especially rare and neglected diseases
- Reduction in R&D investments in pharma; limited willingness of venture capital to invest in long-term projects
- Opportunity to "de-risk" model projects for commercial investment, through a partnership model with private sector and with effective coordination with FDA regulatory science
- Need for enhanced training in relevant disciplines

NIH Institutes and Centers



Catalyzing Collaborations Within NIH



NCATS Research Programs

- Cures Acceleration Network
- Molecular Libraries Program
- Therapeutics for Rare and Neglected Diseases
- Rapid Access to Interventional Development
- Clinical and Translational Science Awards
- FDA-NIH Regulatory Science
- Additional programs identified by NCATS Working Group




A Bold New Paradigm: Cures Acceleration Network

\$100 Million in FY 2012 budget request

- Grant Awards:
 - Up to \$15 million per award per fiscal year
- Partnership Awards:
 - \$1 match for every \$3 from NIH
 - Up to \$15 million per award per fiscal year
- Flexible Research Awards:
 - DARPA-like authority
 - Not to exceed 20% of total appropriated funds in any fiscal year




Catalyzing Collaborations With External Partners



Technologies to Accelerate Discovery

- DNA Sequencing
- Microarray Technology
- Nanotechnology
- New Imaging Modalities
- Computational Biology



mainte

THE INTERNATIONAL WEEKLY JOURNAL OF SCIENCE

THE FUTURE ISBRIGHT

Reflections on the first ten years of the human genomics age

GENOMICS

THE END OF THE BEGINNING

Eric Lander on the impact of the human genome sequence PAGE 187

METHODS

MORE BASES PER DOLLAR

Elaine Mardis on the march of sequencing technology PAGE 198

HEALTH

FROM LAB TO CLINIC

A road map to genomic medicine PAGE 204


O NATURE.COM/NATURE

10 February 2011 \$10



Sequencing Costs Decrease Rapidly





Enhancing the Evidence Base for Health Care

Decisions

The NEW ENGLAND JOURNAL of MEDICINE

THE NEW ENGLAND JOURNAL OF ME

- Prevention
- Diagnosis
- Treatment
- Behavior change
- Health systems
- Special populations



ESTABLISHED IN 1812

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

JOURNAL of MEDICINE

SEPTEMBER 22 2005

, T. Scott Stroup, M.D., M.P.H., Joseph P. McEvoy, M.D., Marvin S. Swartz, M.D., heck, M.D., Diana O. Perkins, M.D., M.P.H., Richard S.E. Keefe, Ph.D., H., Clarence E. Davis, Ph.D., Barry D. Lebowitz, Ph.D., Joanne Severe, M.S., the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators*

VOL. 353 NO. 12


Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

ORIGINAL CONTRIBUTION

and John H. Ip, M.D., for

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

HMO Research Network Collaboratory



- Network of 16 integrated health systems covering >13 million people
- Accelerate large epidemiology studies, clinical trials, and health care services research
- Focus on risk factors, rare diseases, patient accrual, and reimbursement models

New Investigators, New Ideas

- NIH Director's New Innovator Awards
 - Supports exceptionally creative new investigators
 - Must be pursuing innovative, high-impact projects
- NIH Director's Early Independence Awards
 - Young scientists face a long (and lengthening) path from graduate trainee to independent researcher
 - Program provides mechanism to "skip the post-doc"





"Cutting the deficit by gutting our investments in innovation and education is like lightening an overloaded airplane by removing its engine.



It may make you feel like you're flying high at first, but it won't take long before you feel the impact."

President Barack Obama,
 2011 State of the Union

NIH... Turning Discovery Into Health

U.S. Department of Health & Human Services National Institutes of Health

